Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.
Authors
Anthony W. Tolcher
NEXT Oncology, San Antonio, TX;
Anthony W. Tolcher , Wungki Park , Judy S. Wang , Alexander I. Spira , Pasi A. Janne , Ho-Jin Lee , Stanley Gill , Patricia LoRusso , Benjamin Herzberg , Jonathan W. Goldman , Daniel Morgensztern , Jordan Berlin , Anup Kasi , Hisaki Fujii , Meredith Pelster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05382559
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr TPS764)
DOI
10.1200/JCO.2023.41.4_suppl.TPS764
Abstract #
TPS764
Poster Bd #
P20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2023 ASCO Annual Meeting
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
First Author: Jordi Rodon Ahnert
Poster
2020 ASCO Virtual Scientific Program
A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
First Author: Eelke Gort
Poster
2019 ASCO Annual Meeting
A phase I open label study evaluating VT1021 in patients with advanced solid tumors.
First Author: Michael Cieslewicz